A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...

The diagnostic value of primary biliary cholangitis (PBC)-specific antibodies in patients with elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels, and other identifiable ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

I wasn't ill apart from some tiredness.” After being on the organ donor waiting list for four months, Mandy was matched with ...

Genfit SA ( ($GNFT) ) has shared an update. On January 30, 2025, GENFIT announced a significant non-dilutive royalty financing agreement with ...

The following is a summary of “Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has dipped by 38.17%, which has investors questioning if this is right time ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

Inc. (Nasdaq:THAR) ("" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap ...

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two ...